Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02464878 · ClinicalTrials.gov registry record · Phase 2
Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02464878: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT02464878 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02464878, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Patients meeting the study entry criteria will receive 1-3 infusion(s) of in vitro cultured islets. Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.
Interventions
- DRUG Thymoglobulin
- DRUG Etanercept
- DRUG Basiliximab
- DRUG Alpha 1-Antitrypsin
- PROCEDURE Islet Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-01 |
| Est. Completion | 2022-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02464878
The ClinicalTrials.gov registry entry for NCT02464878 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Thymoglobulin is the first listed.
NCT02464878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02464878 about?
NCT02464878 is a clinical study titled "Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant". Patients meeting the study entry criteria will receive 1-3 infusion(s) of in vitro cultured islets. Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.
What is the current status of trial NCT02464878?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2017-01. Estimated completion is 2022-12.
What interventions are being tested in trial NCT02464878?
The interventions under investigation include: Thymoglobulin (DRUG), Etanercept (DRUG), Basiliximab (DRUG), Alpha 1-Antitrypsin (DRUG), Islet Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT02464878?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.